Endometriosis Clinical Trial
Official title:
Observational Open-Label Multicenter Study of Real Clinical Practice to Evaluate the Effects of Hormonal Therapy With Oral Dydrogesterone for Treatment of Confirmed Endometriosis (ORCHIDEA)
NCT number | NCT03690765 |
Other study ID # | DYDR5004 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 27, 2018 |
Est. completion date | May 29, 2020 |
Verified date | June 2019 |
Source | Abbott |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A non-interventional, observational program to assess the effects of dydrogesterone (Duphaston®) 6-months-administration in patients with confirmed endometriosis in a post-marketing setting in the Russian Federation
Status | Completed |
Enrollment | 350 |
Est. completion date | May 29, 2020 |
Est. primary completion date | November 10, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Female, aged = 18 years and = 45 years. - Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS. - External genital endometriosis confirmed by laparoscopy. - Existing pelvic (vaginal) ultrasound data not earlier than 2 months before inclusion in the study. - Prescribed treatment with Duphaston® according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle or continuously. - No hormonal treatment in 2 cycles before enrollment. - Signed Patient Authorization for Use/Disclosure of Data. Exclusion Criteria: - Any co-existing disease(s) needing chronic drug therapy (e.g. Crohn's disease, diabetes etc); Severe concomitant medical illness. - Severe other genital pathology excluding endometriosis (e.g. Multiple/severe myoma; adenomyosis, inflammatory diseases, etc.). - Routine consumption of analgesics other than for the pain of endometriosis. - Patients receiving hormonal contraceptives in last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives etc.). - Ongoing pregnancy. - Menopause or premature ovarian failure. - Contraindications to dydrogesterone treatment listed in the locally approved label (Instructions for the medical use of Duphaston®). - Any other condition that precludes use of dydrogesterone in a particular patient, in accordance with the precautions and special warnings listed in the locally approved label (Instructions for the medical use of Duphaston®). - Abnormal results of pap smear test. - Other conditions that made the patients participation impossible (based on the investigator decision). - Fertility treatments using assisted reproductive technology. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | South Ural State Medical University, Department of Obstetrics and Gynecology | Chelyabinsk | |
Russian Federation | FOTEK Medical Holding LLC, Women's Clinic | Ekaterinburg | |
Russian Federation | Engels Perinatal Center | Engel's | |
Russian Federation | City Hospital ?11 | Kazan | |
Russian Federation | Kemerovo State Medical University, Reshetov Kemerovo Regional Perinatal Center | Kemerovo | |
Russian Federation | Kuban State Medical University. Regional Clinical Hospital ?2 | Krasnodar | |
Russian Federation | Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk Regional Clinical Center for the Protection of Motherhood and Childhood | Krasnoyarsk | |
Russian Federation | Voyno-Yasenetsky Krasnoyarsk State Medical University, Professorial clinic | Krasnoyarsk | |
Russian Federation | Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology | Moscow | |
Russian Federation | Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology | Moscow | |
Russian Federation | RZD Central Clinical Hospital ? 6 | Moscow | |
Russian Federation | Semashko Nizhny Novgorod Regional Clinical Hospital | Novgorod | |
Russian Federation | Clinical Center for Family Health and Reproduction of the Novosibirsk Region | Novosibirsk | |
Russian Federation | Rostov State Medical University, Research institute of obstetrics and pediatrics | Rostov-on-Don | |
Russian Federation | Ott Research Institute of Obstetrics, Gynecology and Reproductology | Saint Petersburg | |
Russian Federation | Pavlov First St. Petersburg State Medical University | Saint Petersburg | |
Russian Federation | Stavropol State Medical University | Stavropol' | |
Russian Federation | State Hospital Perinatal Center | Tyumen | |
Russian Federation | Bashkir State Medical University | Ufa | |
Russian Federation | Clinic "New Medical Technologies" | Voronezh | |
Russian Federation | Voronezh Regional Clinical Hospital ?1, Voronezh Regional Perinatal Center | Voronezh |
Lead Sponsor | Collaborator |
---|---|
Abbott |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in chronic pelvic pain intensity | The changes in chronic pelvic pain intensity assessed by 11-items Numerous Rating Scale (NRS) at the end of observation (Visit 3) versus Baseline (Visit 1) in the prolonged cyclic regime and the continuous regime of Duphaston in patients with endometriosis. The 11-items Numerous Rating Scale (NRS) contains the range from 0 to 10, where 0 represents 'no pain' and 10 represents 'the worst pain'. Patients are asked to point the average pain intensity throughout the last month. The negative change corresponds to better result. | 6 months | |
Secondary | Change in Quality of Life | Changes in Quality of Life assessed by Short Form-20 (SF-20) at the end of observation (Visit3) versus Baseline (Visit1) in patients with endometriosis. The Short Form-20 (Copyright © the RAND Corporation) consists of 20 questions grouped into two parameters: psychological and physical components of health. The indicators of each scale are compiled in such a way that the higher the value of the indicator (from 0 to 100), the better the score on the chosen parameter. | 3 months, 6 months | |
Secondary | Change in chronic pelvic pain intensity | Change in Patient-reported severity of chronic pelvic pain assessed by 11-items NRS after 3-months treatment (Visit2) and after 6-months treatment (Visit3) versus Baseline (Visit1) in patients with endometriosis | 3 months, 6 months | |
Secondary | Cycles' duration | Description of the cycles' duration during 6-months treatment by Duphaston® in patients with endometriosis | 6 months | |
Secondary | Change in dysmenorrhea | Description of the changes in dysmenorrhea assessed by 11-items NRS after 3-months treatment (Visit2) and after 6-months treatment (Visit3) versus Baseline (Visit1) in patients with endometriosis. The 11-items Numerous Rating Scale (NRS) contains the range from 0 to 10, where 0 represents 'No symptoms' and 10 represents 'the Worst trouble'. Patients are asked to point the average intensity of dysmenorrhea symptoms (cyclic pelvic pain, mood disorders, gastro-intestinal symptoms etc.) during the last menses period. The negative change corresponds to better result. | 3 months, 6 months | |
Secondary | Analgesics using | A number of days per each cycle (1-6) when analgesics were self-administered | 6 months | |
Secondary | Sexual wellbeing | Description of the change in sexual wellbeing assessed by A Quality Assessment of Patient-Reported Outcome Measures for Sexual Wellbeing (5-points Likert scale) at the end of observation (Visit3) versus Baseline (Visit1). A Quality Assessment of Patient-Reported Outcome Measures for Sexual Wellbeing by 5-points Likert scale proposes patients to rate themselves on a 5-point scale as being 'very satisfied, satisfied, ordinarily, rather not satisfied, not satisfied'. The number (and proportion) of patients in each category will be presented. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01931670 -
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
|
Phase 3 | |
Recruiting |
NCT05648669 -
A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain
|
Phase 3 | |
Completed |
NCT04081532 -
The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain
|
N/A | |
Recruiting |
NCT06101303 -
Endometriosis Pain
|
||
Completed |
NCT04665414 -
Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
|
||
Recruiting |
NCT05153512 -
ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging (Adodream)
|
||
Active, not recruiting |
NCT04171297 -
Ultrasound Evaluation of the Pelvis in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery
|
||
Recruiting |
NCT04172272 -
The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures
|
N/A | |
Completed |
NCT04565470 -
Strategies of Self-management of Endometriosis Symptoms
|
||
Completed |
NCT03613298 -
Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endometriosis Lesions With Intestinal Involvement.
|
N/A | |
Withdrawn |
NCT05568940 -
Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
|
||
Not yet recruiting |
NCT03464799 -
Does Immunotherapy Have a Role in the Management of Endometriosis?
|
||
Active, not recruiting |
NCT03002870 -
Characteristics of Patient Population With Endometriosis
|
N/A | |
Completed |
NCT02973854 -
Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat
|
||
Withdrawn |
NCT03272360 -
Endometriosis Biomarker Discovery Study
|
N/A | |
Recruiting |
NCT02481739 -
Laparoscopic Surgical Management of Endometriosis on Fertility
|
N/A | |
Active, not recruiting |
NCT02754648 -
Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve
|
N/A | |
Completed |
NCT06106932 -
GnRH-a on Angiogenesis of Endometriosis
|
N/A | |
Completed |
NCT02387931 -
Supplementation in Adolescent Girls With Endometriosis
|
Phase 4 | |
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A |